Hexima Limited lists on ASX

Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing a new prescription treatment for onychomycosis (fungal nail infection), will list on the Australian Securities Exchange (ASX) today after its $3 million public offer closed oversubscribed. View...

read more

AGM 2020 – Results & Recording of Meeting

Please find below the results from the Hexima Limited Annual General Meeting held on 17 November 2020. You may also view the recording of the AGM webcast via the link below. AGM 2020 Meeting Results (pdf) Hexima Limted AGM recording from 17 November 2020

read more

Shareholder Announcement

Hexima Limited has released a shareholder announcement with updates on the following: Lodgment of Prospectus with ASIC Management and Board of Director Changes  First Patient Treated in Phase IIb Clinical Trial  View full announcement (pdf) Hexima Limited Prospectus...

read more

Notice of Extraordinary Meeting & Proxy Form

Please be advised that Hexima Limited (Company) will be holding an Extraordinary General Meeting (EGM) at 11:00am (Melbourne time) on Monday, 5 October 2020 via an audio webcast. Registration will commence at 10:30am. Please see meeting materials below. Meeting...

read more